Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Natural Killer cell control of <italic>BRAF<sup>V600E</sup></italic> mutant melanoma during targeted therapy </title><author><name sortKey="De Andrade, Lucas Ferrari" sort="De Andrade, Lucas Ferrari" uniqKey="De Andrade L" first="Lucas Ferrari" last="De Andrade">Lucas Ferrari De Andrade</name><affiliation><nlm:aff id="af0001"><institution>Immunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute</institution>; Herston, Queensland,<country>Australia</country></nlm:aff></affiliation><affiliation><nlm:aff id="af0002"><institution>Current appointment - Department of Cancer Immunology and AIDS; Dana-Farber Cancer Institute</institution>; Boston, Massachusetts,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Ngiow, Shin Foong" sort="Ngiow, Shin Foong" uniqKey="Ngiow S" first="Shin Foong" last="Ngiow">Shin Foong Ngiow</name><affiliation><nlm:aff id="af0001"><institution>Immunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute</institution>; Herston, Queensland,<country>Australia</country></nlm:aff></affiliation></author><author><name sortKey="Martinet, Ludovic" sort="Martinet, Ludovic" uniqKey="Martinet L" first="Ludovic" last="Martinet">Ludovic Martinet</name><affiliation><nlm:aff id="af0001"><institution>Immunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute</institution>; Herston, Queensland,<country>Australia</country></nlm:aff></affiliation><affiliation><nlm:aff id="af0003"><institution>Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1037; Cancer Research Center of Toulouse (CRCT)</institution>; Toulouse,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name><affiliation><nlm:aff id="af0001"><institution>Immunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute</institution>; Herston, Queensland,<country>Australia</country></nlm:aff></affiliation><affiliation><nlm:aff id="af0004"><institution>School of Medicine; University of Queensland</institution>; Herston, Queensland,<country>Australia</country></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26137412</idno><idno type="pmc">4485837</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485837</idno><idno type="RBID">PMC:4485837</idno><idno type="doi">10.1080/2162402X.2014.998119</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">000214</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000214</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Natural Killer cell control of <italic>BRAF<sup>V600E</sup></italic> mutant melanoma during targeted therapy </title><author><name sortKey="De Andrade, Lucas Ferrari" sort="De Andrade, Lucas Ferrari" uniqKey="De Andrade L" first="Lucas Ferrari" last="De Andrade">Lucas Ferrari De Andrade</name><affiliation><nlm:aff id="af0001"><institution>Immunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute</institution>; Herston, Queensland,<country>Australia</country></nlm:aff></affiliation><affiliation><nlm:aff id="af0002"><institution>Current appointment - Department of Cancer Immunology and AIDS; Dana-Farber Cancer Institute</institution>; Boston, Massachusetts,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Ngiow, Shin Foong" sort="Ngiow, Shin Foong" uniqKey="Ngiow S" first="Shin Foong" last="Ngiow">Shin Foong Ngiow</name><affiliation><nlm:aff id="af0001"><institution>Immunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute</institution>; Herston, Queensland,<country>Australia</country></nlm:aff></affiliation></author><author><name sortKey="Martinet, Ludovic" sort="Martinet, Ludovic" uniqKey="Martinet L" first="Ludovic" last="Martinet">Ludovic Martinet</name><affiliation><nlm:aff id="af0001"><institution>Immunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute</institution>; Herston, Queensland,<country>Australia</country></nlm:aff></affiliation><affiliation><nlm:aff id="af0003"><institution>Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1037; Cancer Research Center of Toulouse (CRCT)</institution>; Toulouse,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name><affiliation><nlm:aff id="af0001"><institution>Immunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute</institution>; Herston, Queensland,<country>Australia</country></nlm:aff></affiliation><affiliation><nlm:aff id="af0004"><institution>School of Medicine; University of Queensland</institution>; Herston, Queensland,<country>Australia</country></nlm:aff></affiliation></author></analytic><series><title level="j">Oncoimmunology</title><idno type="ISSN">2162-4011</idno><idno type="eISSN">2162-402X</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Pharmacologic inhibition of the mutant BRAF<sup>V600E</sup> protein in advanced BRAF<sup>V600E</sup> melanoma results in a high proportion of patients that respond, but few with durable responses. We have recently revealed that Natural Killer (NK) cells play an essential role in the <italic>BRAF<sup>V600E</sup></italic> inhibitor control of melanoma metastases in mice that may be therapeutically exploited to help overcome drug resistance.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Oncoimmunology</journal-id><journal-id journal-id-type="iso-abbrev">Oncoimmunology</journal-id><journal-id journal-id-type="pmc">KONI</journal-id><journal-title-group><journal-title>Oncoimmunology</journal-title></journal-title-group><issn pub-type="ppub">2162-4011</issn><issn pub-type="epub">2162-402X</issn><publisher><publisher-name>Taylor & Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26137412</article-id><article-id pub-id-type="pmc">4485837</article-id><article-id pub-id-type="publisher-id">998119</article-id><article-id pub-id-type="doi">10.1080/2162402X.2014.998119</article-id><article-categories><subj-group subj-group-type="heading"><subject>Author's View</subject></subj-group></article-categories><title-group><article-title>Natural Killer cell control of <italic>BRAF<sup>V600E</sup></italic> mutant melanoma during targeted therapy </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>de Andrade</surname><given-names>Lucas Ferrari</given-names></name><xref ref-type="aff" rid="af0001"><sup>1</sup></xref><xref ref-type="aff" rid="af0002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ngiow</surname><given-names>Shin Foong</given-names></name><xref ref-type="aff" rid="af0001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Martinet</surname><given-names>Ludovic</given-names></name><xref ref-type="aff" rid="af0001"><sup>1</sup></xref><xref ref-type="aff" rid="af0003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Smyth</surname><given-names>Mark J</given-names></name><xref ref-type="aff" rid="af0001"><sup>1</sup></xref><xref ref-type="aff" rid="af0004"><sup>4</sup></xref><xref ref-type="corresp" rid="an0001"><sup>*</sup></xref></contrib><aff id="af0001"><label>1</label><institution>Immunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute</institution>; Herston, Queensland,<country>Australia</country></aff><aff id="af0002"><label>2</label><institution>Current appointment - Department of Cancer Immunology and AIDS; Dana-Farber Cancer Institute</institution>; Boston, Massachusetts,<country>USA</country></aff><aff id="af0003"><label>3</label><institution>Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1037; Cancer Research Center of Toulouse (CRCT)</institution>; Toulouse,<country>France</country></aff><aff id="af0004"><label>4</label><institution>School of Medicine; University of Queensland</institution>; Herston, Queensland,<country>Australia</country></aff></contrib-group><author-notes><corresp id="an0001"><label>*</label>Correspondence to: Mark J Smyth; Email: <email xlink:href="Mark.Smyth@qimrberghofer.edu.au">Mark.Smyth@qimrberghofer.edu.au</email></corresp></author-notes><pub-date pub-type="epub"><day>1</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2015</year></pub-date><volume>4</volume><issue>4</issue><elocation-id seq="3">e998119</elocation-id><history><date date-type="received"><day>5</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>9</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>© 2015 Taylor & Francis Group, LLC</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Taylor & Francis Group, LLC</copyright-holder></permissions><self-uri content-type="pdf" xlink:href="koni-04-04-998119.pdf"></self-uri><abstract><p>Pharmacologic inhibition of the mutant BRAF<sup>V600E</sup> protein in advanced BRAF<sup>V600E</sup> melanoma results in a high proportion of patients that respond, but few with durable responses. We have recently revealed that Natural Killer (NK) cells play an essential role in the <italic>BRAF<sup>V600E</sup></italic> inhibitor control of melanoma metastases in mice that may be therapeutically exploited to help overcome drug resistance.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>BRAF</kwd><kwd>cancer immunotherapy</kwd><kwd>metastases</kwd><kwd>NK cells</kwd><kwd>resistance</kwd></kwd-group><counts><fig-count count="1"></fig-count><table-count count="0"></table-count><ref-count count="10"></ref-count><page-count count="3"></page-count></counts></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0002140 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0002140 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |